SOUTH SAN FRANCISCO, Calif., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical development company with a focus on innovative therapies for patients with debilitating diseases, today announced that it has commenced an underwritten public offering of 3,000,000 shares of its common stock. In addition, Atara Bio expects to grant the underwriters a 30-day option to purchase up to an additional 450,000 shares. All of the shares in the offering will be sold by Atara Bio.
Goldman, Sachs & Co. and Citigroup Global Markets Inc. are acting as joint book-running managers for the proposed offering. Jefferies LLC is acting as co-manager.
A registration statement related to the offering has been filed with the Securities and Exchange Commission but has not yet become effective.
The offering is being made only by means of a written prospectus forming part of the effective registration statement. Copies of the preliminary prospectus relating to the offering may be obtained, when available, from Goldman, Sachs & Co., Attention: Prospectus Department, 200 West Street, New York, New York 10282, by telephone at (866) 471-2526, by facsimile at (212) 902-9316, or by email at firstname.lastname@example.org, or from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, by email at email@example.com or by phone at (800) 831-9146.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is a biopharmaceutical development company focusing on innovative therapies for patients with debilitating diseases. Atara Bio's lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Bio entered into an exclusive option agreement with Memorial Sloan Kettering Cancer Center (MSK) under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by Atara Bio.
Forward Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Because such statements deal with future events and are based on Atara Bio's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Atara Bio could differ materially from those described in or implied by the statements in this press release. For example, forward-looking statements include statements regarding Atara Bio's proposed public offering. These forward-looking statements are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in Atara Biotherapeutics, Inc.'s quarterly report on Form 10-Q for the quarter ended September 30, 2014, filed with the Securities and Exchange Commission (SEC) on November 12, 2014 and subsequent filings with the Securities and Exchange Commission. Except as otherwise required by law, Atara Bio disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.